MSD to establish production of three vaccines in Russia

17 July 2019

US pharma giant Merck & Co (NYSE: MRK), known as MSD outside of the USA and Canada, will transfer the technology for the production of vaccines against chickenpox, rotavirus and human papillomavirus (HPV) to the Russian drugmaker Rostec, with the aim of a further localization of its manufacturing within the country, according to recent statements by the companies.

It is planned the production of vaccines may be started at the facilities of Rostec’s Fort site in the Ryazan region already within the next several months, reports The Pharma Letter’s local correspondent.

The total value of investment in the project is estimated at 7 billion roubles ($112 million). Under the terms of the collaboration, MSD and Rostec will start the production of vaccines for the prevention of rotavirus infection (RotaTeq), chicken pox (Varivax), and HPV (Gardasil).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK